Safety study of KONECT RESILIA heart valve replacement
Part of Heart & circulation clinical trials.
This study tracks how well a new artificial aortic valve and aorta graft (called KONECT RESILIA) work after surgery in real-world patients. Researchers want to understand if it's safe and performs well over time in people who need this valve replaced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Have a diseased aortic valve (your heart's main valve) and a damaged ascending aorta (the main artery leaving your heart) that need surgical replacement
- Planning to receive the KONECT RESILIA aortic valved conduit (the device being studied)
- No active heart infection (endocarditis) or heart infection in the past 3 months
- Able to commit to study follow-up visits and requirements
- Kidney function adequate enough to not require dialysis (eGFR above 30)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information on people who receive the INSPIRIS RESILIA aortic valve as part of their regular care. Researchers want to see how well the valve works in everyday practice.
This trial tests how well a new replacement heart valve works and how safe it is. You might qualify if you need a planned first-time aortic valve replacement and are 60-70 years old (or younger if you cannot take blood thinners).
This trial tests how safe and effective a new artificial aortic valve (Venus-Neo) is for people who need an aortic valve replacement. It may help by offering another option, while researchers closely track outcomes after the procedure.
This study is for people with a severe leaking aortic valve (aortic regurgitation) who are too high-risk for open-heart surgery. It tracks how well a less-invasive valve replacement (TAVI) using the JenaValve or J-Valve works for them.
This trial tests a new heart valve device (Venus-Vitae) for people with severe aortic stenosis, a condition where the heart valve is too tight. It aims to see if the device works well for patients of all surgical risk levels.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
Hear when a new Aortic Valve Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.